投稿

12月, 2022の投稿を表示しています

Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  Expert Opinion on Drug Safety. 2022:1-8

イメージ
    Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.  Expert Opinion on Drug Safety. 2022:1-8.  

頭痛講演 2022年12月7日、20日

イメージ
 

AJOVY MIGRAINE EXPERT MEETING 2022 Dec 11

イメージ
 

第3回 歯科医のためのHeadache Academy

イメージ
 

Kikui S, Chen Y, Ikeda K, Hasebe M, Asao K, Takeshima T.  BMJ Open. 2022;12(11):e065787.

イメージ
    Kikui S, Chen Y, Ikeda K, Hasebe M, Asao K, Takeshima T.  Comorbidities in patients with migraine in Japan: a cross-sectional study using data from National Health and Wellness Survey.  BMJ Open. 2022;12(11):e065787. https://www.ncbi.nlm.nih.gov/pubmed/36450434 https://bmjopen.bmj.com/content/bmjopen/12/11/e065787.full.pdf 2022/12/01